Shannon Jackson

Contact Information
Providence Health Care, St. Paul’s Hospital
Department of Hematology
#440 – 1144 Burrard Street
Vancouver, BC, Canada, V6Z 2A5
Tel: 1-604-684-5794
Fax: 1-604-684-5705
Email: Dr.Jackson@providencehematology.com

Current Positions

  • Clinical Associate Professor, Hematology/Bone Marrow Transplant, Medicine.
  • Staff Hematologist, Providence Health Care.

Research Interests

Inherited bleeding disorders including hemophilia, von Willebrand disease, rare coagulation factor deficiencies and hereditary platelet function disorders illustrate the consequence of both known and unknown genetic mutations in various coagulation proteins and platelet biological mechanisms. Medical care for these disorders is specialized and multidisciplinary. In British Columbia, I have had the opportunity to recently join the Provincial Adult Hemophilia and Bleeding Disorders Comprehensive Care program at St. Paul’s Hospital. I am interested in providing optimal clinical care to this unique group of patients and pursuing both clinical and translational research to 1) further our understanding of the coagulation system, especially in bleeding disorders that are less well defined, 2) improve the treatments available to those with bleeding disorders, 3) appreciate how aging impacts those with inherited bleeding disorders such as hemophilia.

Publications

  1. Jackson S, Santoro C, Gue D, Ferretti A, Gaglioti D, Squire S, Mazzucconi MG, Hermans C. Clinical practice of personalized prophylaxis in hemophilia: illustrations of experiences and benefits from two continents. Clinical Case Reports, In press 2019.
  2. Sun HL, Chan S, Yenson P and Jackson S. Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit.  Clinical & Applied Thrombosis/Hemostasis. 24(2):303-309, 2018 Mar.
  3. Roberts J, Lattimore S, Recht M, Jackson S, Gue D, Squire S, Robinson K.S., Price V, Denne M, Richardson S, and Rockwood, Kenneth. Goal Attainment Scaling for Haemophilia (GAS-Hēm): testing the feasibility of a new patient-centric outcome measure in people with haemophilia. Haemophilia 2018 In Press.
  4. Loomans JI, van Velzen AS, Peters M, Kruip M, Platokouki H, Jackson S, Carcao M, Santagostino E, Beckers E, Voorberg J, van der Bom JG, and Fijnvandraat K for the RISE consortium. DDAVP in moderate hemophilia A patients: a treatment strategy worth considering. Haematologica 2017. In press.
  5. Strike K, Uy M, Lawson W, Squire S, Jackson S, Stein N, Iorio A, Chan A. Point of care ultrasonography in haemophilia care: training and competency for muscular haematomas. Hemophilia 2017. In press.
  6. Sun L, McIntosh K, Squire S, Yang M, Bartholomew C, Gue D, Camp P, Jackson S. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A. Haemophilia 2017 Nov;23(6):877-883.
  7. Sun L, Yang M, Fung M, Chan S, Jawi M, Anderson T, Poon M-C; Jackson S. Adult males with hemophilia have a different macrovascular and microvascular endothelial function profile compared with healthy controls. Haemophilia 2017 Sep;23(5):777-783.
  8. Keepanasseril A, Stoffman J, Bouskill V, Carcao C, Iorio A, Jackson S, on behalf of the Association of Hemophilia Centre Directors of Canada (AHCDC). Switching to Extended Half-life products in Canada – Preliminary data. Haemophilia 2017, DOI: 10.1111/hae.13245.
  9. Sun L, McIntosh K, Woo C, Crilly E, Bartholomew C, Gue D, De Marchi L, Squire S, Silva A, Yang M, Wu J, Jackson S. Prevalence and predictors of loss to follow-up in young adults with mild hemophilia. Haemophilia 2017;23(1): e36–e39.
  10. Recht M, Konkle BA, Jackson S, Neufeld EJ, Rockwood K, Pipe S. Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era. Haemophilia 2016; 22 (6): 825–832.
  11. Sun H, Yang M, Sait A, von Drygalski A, Jackson S. Hematuria is Not a Risk Factor of Hypertension or Renal Impairment in Patients with Hemophilia. Haemophilia 2016; 22(4): 549–555.
  12. Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S,  Hanabusa H, Pasi J,  Pabinger I, Jackson S, Cristiano L, Li X, Pierce G, Allen G.  Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 2016; 22(1): 72-80.
  13. Gue D, Squire S, McIntosh K, Bartholomew C, Summers N, Sun H, Yang M, Jackson S. Joining the patient on the path to customized prophylaxis:  One hemophilia team explores the tools of engagement. Journal of Multidisciplinary Care 2015; 8:527-534.
  14. Minuk L, Jackson S, Iorio A, Poon M-C, Dilworth E, Card R, Brose K, Chin-Yee B, Rizwaan I, Louzada M. Cardiovascular Disease in Canadians with Hemophilia: Age Related Cardiovascular Disease in Hemophilia Epidemiological Research (ARCHER Study). Haemophilia 2015; 21(6): 736-741.
  15. Strike K, Iorio A, Jackson S, Lawson W, Scott L, Squire S, Chan A. Point of care ultrasonography in hemophilia care: recommendations for training and competency evaluation. Haemophilia 2015; 21(6): 828-831.
  16. Wang S, Yang M, Jackson S. Pain management strategies in adults with haemophilia: A retrospective study. Haemophilia 2015. 21(6): e487-489.
  17. Kalmar L, Jackson S, Gue D, Oliffe JL, Currie LM. Men, Masculinities and Hemophilia. American Journal of Mens Health 2015. 1557988315596362, first published on July 29, 2015.
  18. Jackson SC, Yang M, Minuk L, Sholzberg M, St-Louis J, Iorio A, Card R and Poon MC. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematology 2015, 15:4.
  19. Rizwan I, Minuk L, Jackson S, Iorio A. Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. Haemophilia; 2014 DOI: 10.1111/hae.12596.
  20. Kwok J, Gue D, Curtis J, Jackson S. Pharmacists have a key role in raising awareness around risks of intranasal desmopressin. Journal of the American Pharmacist’s Association 2014; DOI 10.1331/JAPhA. 2014.14538.
  21. Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang J, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. British Journal of Haematology 2014 DOI: 10.1111/bjh.13112.
  22. Jackson S, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon M-C. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe hemophilia B. Haemophilia 2014; 20:e199-e204.
  23. Smith NC, Bartholomew C, Jackson S. Issues in the ageing individual with haemophilia and other inherited bleeding disorders: understanding and responding to the patients’ perspective. Haemophilia 2014: 20:e1-e6.
  24. Ho S, Gue D, McIntosh K, Bucevska M, Yang M, Jackson SC. An objective method for assessing adherence to prophylaxis in adults with severe hemophilia. Haemophilia 2014;20(1):39-43.

Education

  • Bayer International Hemophilia Scholarship/Hemostasis Fellowship, University of Calgary, 2009.
  • Hematology Residency, University of Calgary, 2007.
  • MD, University of Calgary, 2001.